GTX 011 - GAT Therapeutics
Alternative Names: GTX-011 - GAT Therapeutics; GTX-11Latest Information Update: 28 Feb 2026
At a glance
- Originator GAT Therapeutics
- Class Antifibrotics; Hepatoprotectants; Skin disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Idiopathic pulmonary fibrosis; Pulmonary fibrosis
- Preclinical Systemic scleroderma
- No development reported Hepatic fibrosis; Myelofibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for preclinical development in Hepatic-fibrosis in Spain (PO)
- 28 Feb 2026 No recent reports of development identified for research development in Myelofibrosis in Spain (PO)
- 28 Dec 2025 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Spain (PO)